Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert B Raffa

Showing results (81-90 of 195) with videos related to

Pageof 20
Sort By:
Neuroscience Letters|August 17, 2010
5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planariansScott M Rawls, Hardik Shah, George Ayoub, et al.
Pain and Therapy|October 16, 2016
Change Pain: Ever Evolving-An Update for 2016Joseph V Pergolizzi, Antonella Paladini, Giustino Varrassi, et al.
Expert Opinion on Investigational Drugs|March 15, 2013
Opioid antagonists for painRobert Taylor, Joseph V Pergolizzi, Frank Porreca, et al.
Behavioural Pharmacology|June 1, 2010
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planariansScott M Rawls, Tavni Patil, Ekaternia Yuvasheva, et al.
Amino Acids|August 19, 2011
Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assayChris Tallarida, Kevin Song, Robert B Raffa, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2002
Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase AShawn D Spencer, Oluseyi Abdul, Robert J Schulingkamp, et al.
Journal of Pharmacological and Toxicological Methods|December 15, 2004
A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in PlanariaSumiyo Umeda, Gregory W Stagliano, Michael R Borenstein, et al.
Expert Opinion on Drug Delivery|May 10, 2018
What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholdersJoseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, et al.
Journal of Clinical Pharmacy and Therapeutics|April 29, 2021
Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality?John F Peppin, Joseph V Pergolizzi, Albert Dahan, et al.
Journal of Clinical Pharmacy and Therapeutics|June 10, 2021
Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limitJoseph V Pergolizzi, Albert Dahan, Jo Ann LeQuang, et al.
Pageof 20

Showing results (81-90 of 195) with videos related to

Sort By:
Pageof 20
Neuroscience Letters|August 17, 2010
5-HT(1A)-like receptor activation inhibits abstinence-induced methamphetamine withdrawal in planariansScott M Rawls, Hardik Shah, George Ayoub, et al.
Pain and Therapy|October 16, 2016
Change Pain: Ever Evolving-An Update for 2016Joseph V Pergolizzi, Antonella Paladini, Giustino Varrassi, et al.
Expert Opinion on Investigational Drugs|March 15, 2013
Opioid antagonists for painRobert Taylor, Joseph V Pergolizzi, Frank Porreca, et al.
Behavioural Pharmacology|June 1, 2010
First evidence that drugs of abuse produce behavioral sensitization and cross sensitization in planariansScott M Rawls, Tavni Patil, Ekaternia Yuvasheva, et al.
Amino Acids|August 19, 2011
Glutamate carboxypeptidase II (GCPII) inhibitor displays anti-glutamate and anti-cocaine effects in an invertebrate assayChris Tallarida, Kevin Song, Robert B Raffa, et al.
The Journal of Pharmacology and Experimental Therapeutics|May 23, 2002
Toward the design of ribonuclease (RNase) inhibitors: ion effects on the thermodynamics of binding of 2'-CMP to RNase AShawn D Spencer, Oluseyi Abdul, Robert J Schulingkamp, et al.
Journal of Pharmacological and Toxicological Methods|December 15, 2004
A reverse-phase HPLC and fluorescence detection method for measurement of 5-hydroxytryptamine (serotonin) in PlanariaSumiyo Umeda, Gregory W Stagliano, Michael R Borenstein, et al.
Expert Opinion on Drug Delivery|May 10, 2018
What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholdersJoseph V Pergolizzi, Robert Taylor, Jo Ann LeQuang, et al.
Journal of Clinical Pharmacy and Therapeutics|April 29, 2021
Are opioid receptor antagonists adequate for "Opioid" overdose in a changing reality?John F Peppin, Joseph V Pergolizzi, Albert Dahan, et al.
Journal of Clinical Pharmacy and Therapeutics|June 10, 2021
Overdoses due to fentanyl and its analogues (F/FAs) push naloxone to the limitJoseph V Pergolizzi, Albert Dahan, Jo Ann LeQuang, et al.
Pageof 20